<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FENOLDOPAM MESYLATE</span><br/>(fen-ol'do-pam mes'y-late)<br/><span class="topboxtradename">Corlopam<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">antihypertensive</span>; <span class="classification">non-nitrate vasodilator</span>; <span class="classification">dopamine agonist agent</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Rapid-acting vasodilator that is a dopamine D<sub>1</sub>-like receptor agonist. Exerts hypotensive effects by decreasing peripheral vascular resistance while increasing renal blood
         flow, diuresis, and natriuresis.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Indicated by rapid reduction in BP. Decreases both systolic and diastolic pressures.</p>
<h1><a name="uses">Uses</a></h1>
<p>Short-term (up to 48 h) management of severe hypertension.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to fenoldopam. Avoid concomitant use with beta blockers.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Asthmatic patients; hepatic cirrhosis, portal hypertension, or variceal bleeding; arrhythmias, tachycardia, or angina, particularly
         unstable angina; elevated IOP; angular-closure glaucoma; hypotension; hypokalemia; acute cerebral infarct or hemorrhage; pregnancy
         (category B), lactation. Safety and efficacy in children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Severe Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.0250.3 mcg/kg/min by continuous infusion for up to 48 h, may increase by 0.050.1 mcg/kg/min q15min (dosage range:
               0.011.6 mcg/kg/min)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Continuous:</span> Dilute to a final concentration of 40 mcg/mL by adding 1 mL (10 mg), 2 mL (20 mg), or 3 mL (30 mg) of fenoldopam to 250, 500,
                  or 1000 mL, respectively, of NS or D5W.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Continuous:</span>  Give only by continuous infusion; never give a direct or bolus dose. Titrate initial dose up or down no more frequently than
                  q15min.  
               </p>
<ul>
<li>
                     						Note: Diluted solution is stable under normal room temperature and light for 24 h. Discard any unused solution after 24 h.
                     					
                  </li>
<li>Store at 15°30° C (59°86° F) in a tightly closed container and protect from light.</li>
</ul>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Y-site:</span>
<b>Aminophylline,</b>
<b> ampicillin,</b>
<b> amphotericin B,</b>
<b> bumetanide, </b>
<b>cefoxitin, </b>
<b>dexamethasone, </b>
<b>diazepam,</b>
<b> fosphenytoin,</b>
<b> furosemide,</b>
<b> ketorolac,</b>
<b> methohexital,</b>
<b> methylprednisolone,</b>
<b> pentobarbital,</b>
<b> phenytoin,</b>
<b> prochlorperazine,</b>
<b> sodium bicarbonate,</b>
<b> thiopental.</b>
</p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Injection site reaction, pyrexia, nonspecific chest pain. <span class="typehead">CNS:</span> Headache, nervousness, anxiety, insomnia, dizziness. <span class="typehead">CV:</span>
<span class="speceff-common">Hypotension, tachycardia,</span> T-wave inversion, flushing, postural hypotension, extrasystoles, palpitations, bradycardia, heart failure, ischemic heart
      disease, <span class="speceff-life">MI</span>, angina. <span class="typehead">GI:</span> Nausea, vomiting, abdominal pain or fullness, constipation, diarrhea. <span class="typehead">Metabolic:</span> Increased creatinine, BUN, glucose, transaminases, LDH; hypokalemia. <span class="typehead">Respiratory:</span> Nasal congestion, dyspnea, upper respiratory disorder. <span class="typehead">Skin:</span> Sweating. <span class="typehead">Other:</span> UTI, leukocytosis, bleeding. 
      <h1><a name="interactions">Interactions</a></h1>No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 5 min. <span class="typehead">Peak:</span> 15 min. <span class="typehead">Duration:</span> 1530 min. <span class="typehead">Distribution:</span> Crosses placenta. <span class="typehead">Metabolism:</span> Conjugated in liver. <span class="typehead">Elimination:</span> 90% excreted in urine, 10% in feces. <span class="typehead">Half-Life:</span> 5 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP and HR carefully at least q15min or more often as warranted; expect dose-related tachycardia.</li>
<li>Lab tests: Carefully monitor serum electrolytes (especially serum potassium), BUN and creatinine, liver enzymes, and blood
            glucose &amp; HbA<sub>1c</sub>.
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>